93 matching material contract exhibits.
Rallybio Corp
**Exhibit 10.32 **
**AVENZO THERAPEUTICS, INC. **
**COMMON STOCK PURCHASE AGREEMENT **
This Common Stock Purchase Agreement (the “Agreement”) is made as of [ ] by and between Avenzo Therapeutics, Inc., a Delaware corporation (the “Company”) and [ ] (“Purchaser”). Certain capitalized terms used below are defined in the terms and conditions set forth in Exhibit A attached to this Agreement, which are incorporated by reference.
…
Rallybio Corp
**Exhibit 10.37 **
**CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE AVENZO THERAPEUTICS, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO AVENZO THERAPEUTICS, INC. IF PUBLICLY DISCLOSED. **
**COLLABORATION, EXCLUSIVE OPTION AND LICENSE AGREEMENT **
**by and between **
AVENZO THERAPEUTICS, INC.
**and **
**VELAVIGO (SHANGHAI) LIMITED **
**and **
**for purposes of Sections 5.8 and 5.9 and Articles 18 and 19, **
**VELAVIGO BIO, INC. **
**dated as of November 16, 2024 **
**TABLE OF CONTENTS **
…
Rallybio Corp
**Exhibit 10.41 **
***FIRST AMENDMENT TO OFFICE LEASE ***
This FIRST AMENDMENT TO OFFICE LEASE (this “First Amendment”) is made and entered into as of December 6, 2024, by and between KR JUNCTION, LLC, a Delaware limited liability company (“Landlord”), and AVENZO THERAPEUTICS, INC., a Delaware corporation (“Tenant”).
R E C I T A L S :
A. Landlord (as successor-in-interest to BRE CA OFFICE OWNER LLC, a Delaware limited liability company) and Tenant entered into that certain Office Lease dated 11/7/2022 (the “Lease”), whereby Landlord leases to Tenant and Tenant leases from Landlord those certain premises consisting of 17,223 rentable square feet (collectively, the “Existing Premises”) comprised of: (i) that certain space consisting of 5,960 rentable square feet of space commonly known as Suite 250 (“Suite 250”) and located on the second (2nd) floor of that certain building (the “Building”) located at 12707 High Bluff Drive, San Diego, California 92130, and (ii) that certain space consisting of 11,263 rentable square feet of space com
…
Rallybio Corp
**Exhibit 10.40 **
***OFFICE LEASE ***
11/7/2022
This Office Lease (this “Lease”) is dated November ___, 2022, by and between BRE CA OFFICE OWNER LLC, a Delaware limited liability company (“Landlord”) and AVENZO THERAPEUTICS, INC., a Delaware corporation (“Tenant”). The following exhibits are incorporated herein and made a part hereof: Exhibit A-1 (Outline of Suite 250, Suite 200, and Potential Offering Space [Suite 225]); Exhibit A-2 (Outline of Temporary Space); ***Exhibit ***B (Expenses and Taxes); Exhibit C-1 (Suite 250 Tenant Work Letter); Exhibit C-2 (Suite 200 Tenant Work Letter); ***Exhibit ***D (Form of Confirmation Letter); ***Exhibit ***E (Rules and Regulations); ***Exhibit ***F (Additional Provisions); ***Exhibit ***G (Judicial Reference); Exhibit H (Form of Letter of Credit); Exhibit I (Approximate Location of Signage).
**1 BASIC LEASE INFORMATION. **
1.1 Premises.
…
Rallybio Corp
**Exhibit 10.31 **
**AVENZO THERAPEUTICS, INC. **
**2022 EQUITY INCENTIVE PLAN **
**ADOPTED BY THE BOARD OF DIRECTORS: AUGUST 15, 2022| **
**APPROVED BY THE STOCKHOLDERS: AUGUST 15, 2022 **
**AMENDED BY THE BOARD OF DIRECTORS: AUGUST 17, 2022 **
**AMENDED BY THE BOARD OF DIRECTORS: SEPTEMBER 13, 2022 **
**AMENDED BY THE BOARD OF DIRECTORS: MARCH 6, 2023 **
**APPROVED BY THE STOCKHOLDERS: MARCH 6, 2023 **
**AMENDED BY THE BOARD OF DIRECTORS: MARCH 11, 2024 **
**APPROVED BY THE STOCKHOLDERS: MARCH 11, 2024 **
**AMENDED BY THE BOARD OF DIRECTORS: MARCH 21, 2024 **
**APPROVED BY THE STOCKHOLDERS: MARCH 21, 2024 **
**AMENDED BY THE BOARD OF DIRECTORS: NOVEMBER 4, 2024 **
**APPROVED BY THE STOCKHOLDERS: NOVEMBER 4, 2024 **
**AMENDED BY THE BOARD OF DIRECTORS: JUNE 6, 2025 **
**APPROVED BY THE STOCKHOLDERS: JUNE 16, 2025 **
**AMENDED BY THE BOARD OF DIRECTORS: AUGUST 21, 2025 **
**APPROVED BY THE STOCKHOLDERS: AUGUST 21, 2025 **
**AMENDED BY THE BOARD OF DIRECTORS: SEPTEMBER 17, 2025 **
**APPROVED BY THE STOCKHOLDERS: SEPTEMBER 17, 2025 **
…
Sono Group S.a r.l.
** **
**INDEMNITY AGREEMENT **
THIS INDEMNITY AGREEMENT (this “Agreement”) is made as of ________, 2026, by and between Sono Group, Inc., a Delaware corporation (the “Company”), and _________ (“Indemnitee”).
***RECITALS ***
WHEREAS, highly competent persons have become more reluctant to serve publicly-held corporations as directors, officers or in other capacities unless they are provided with adequate protection through insurance or adequate indemnification against inordinate risks of claims and actions against them arising out of their service to and activities on behalf of such corporations;
…
Pulmatrix, Inc.
Termination Agreement
This Termination Agreement (this “Agreement”) is entered into this 29th day of June, 2026, by and among Pulmatrix, Inc. (the “Parent”), EOS Senolytix, Inc. (the “Company”) and Senotherapeutix, Inc. (the “Stockholder”).
WHEREAS, on March 26, 2026, the Parent, the Company and PUOS Merger Sub, Inc. and entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”); and
WHEREAS, on March 26, 2026, the parties hereto entered into that certain Company Stockholder Support Agreement (the “Support Agreement”) whereby the Stockholder agreed to certain covenants including but not limited to voting their shares of the Company in favor of the Merger Agreement;
WHEREAS, the parties desire to enter into this Agreement for the purpose of terminating the Support Agreement effective immediately pursuant to Section 10(c) of the Support Agreement; and
…
Pulmatrix, Inc.
Stockholders’ Agreement
among
EOS SENOLYTIX, INC.
and
each person identified on schedule a
dated as of
October 15, 2024
TABLE OF CONTENTS
| articlE I Definitions | 1 | ||
| ARTICLE II Management and Operation of the Corporation | 5 | ||
| Section 2.01 | Board of Directors | 5 |
…
Pulmatrix, Inc.
License and Services AGreement
This Services and License Agreement (“Agreement”) is made and entered into as of the 9th day of February, 2026 (“Effective Date”) by and between SENOTHERAPEUTIX, Inc., a Delaware company with an address at (“SENOTHERAPEUTIX”) and Eos SENOLYTIX, Inc., a Delaware company with an address at (“Eos”). SENOTHERAPEUTIX and Eos are each referred to herein individually as a “Party” and collectively as the “Parties.”
Recitals
WHEREAS, SENOTHERAPEUTIX owns or controls certain intellectual property rights, access to certain facilities and possess certain resources useful for research and development of geropeptides and oncopeptides and related technologies;
WHEREAS, Eos was formed to research and develop specific therapeutic programs as further defined herein; and
…
Pulmatrix, Inc.
EOS SENOLYTIX, INC.
** **
SUBSCRIPTION AGREEMENT AND INVESTOR QUESTIONNAIRE
** **
Your investment in Eos SENOLYTIX, INC. (the “Company”) can only be made by means of the completion, delivery and acceptance of the subscription documents in this package.
Please complete and submit, to the address set forth below, the following documents:
…
Pulmatrix, Inc.
LICENSE AGREEMENT
This License Agreement (the “Agreement”) is effective April 1, 2026 (the “Effective Date”), between K2 Biolabs, Inc., a Delaware corporation, as Licensor (the “Licensor”), and Eos SENOLYTIX as Licensee (the “Licensee”). Licensor and Licensee are sometimes referred to herein, individually, as a “Party” or, collectively, as “Parties.”
RECITALS
WHEREAS:
…
Pulmatrix, Inc.
AMENDED AND RESTATED
SECURITIES PURCHASE AGREEMENT
Effective as of April 9, 2026
This Amended and Restated Securities Purchase Agreement (this “Agreement”), effective as of the date first set forth above (the “Effective Date”), is entered into by and among Eos SENOLYTIX, Inc., a Delaware corporation (the “Company”), and the persons and entities (each individually a “Purchaser,” and collectively, the “Purchasers”) named on the Schedule of Purchasers attached hereto as Schedule A (the “Schedule of Purchasers”).
** **
WHEREAS, on March 26, 2026, the Company and the Purchasers entered into that certain Securities Purchase Agreement (the “Original Agreement”) pursuant to which, amongst other things, the Purchasers committed to fund convertible promissory notes and purchase shares of Class A Common Stock of the Company;
…